Julie Kanter MD

Abstracts/Posters

• Severity Classification for Sickle Cell Disease: A RAND/UCLA Modified Delphi Panel
  Julie Kanter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy
  Julie Kanter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene Therapy
  Julie Kanter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Impact of Different Pediatric Estimated GFR Equations on Reporting of Renal Outcoms
  Julie Kanter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Barriers and Facilitators to Transcranial Doppler Screening for Stroke Prevention in Children with Sickle Cell Anemia: Results from the Displace Consortium
  Julie Kanter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study
  Julie Kanter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Advancing Science in Sickle Cell Disease: Implications for the Future of Care 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Characteristics of Children with Abnormal TCD in the Modern Era: Results from the Displace Consortium 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Pediatric Clinical Non-Malignant Hematology 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Established Prevention of Vaso-Occlusive Crises with Crizanlizumab Is Further Improved in Patients Who Follow the Standard Treatment Regimen: Post-Hoc Analysis of the ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all